Asset Details
Do you wish to reserve the book?
Marburg and Sudan virus outbreaks: are we any closer to a pan-filovirus vaccine?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Marburg and Sudan virus outbreaks: are we any closer to a pan-filovirus vaccine?
Do you wish to request the book?
Marburg and Sudan virus outbreaks: are we any closer to a pan-filovirus vaccine?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Marburg and Sudan virus outbreaks: are we any closer to a pan-filovirus vaccine?
2026
Overview
Filoviruses, including Ebola, Marburg, and Sudan viruses, cause severe hemorrhagic fevers with high mortality rates and outbreaks. While recent vaccine developments such as the rVSV-ZEBOV vaccine for Ebola have marked important progress and is now licensed by the FDA and the EMA, they remain virus-specific and limited in scope. The urgent need for a broad, cross-protective pan-filovirus vaccine is clear, especially considering recurring outbreaks and the potential for global spread. This paper reviews the current landscape of filovirus vaccine research, highlighting promising platforms, challenges in achieving cross-species protection, and lessons learned from past public health responses. It also emphasizes the scientific and logistical hurdles, such as antigenic diversity and the sporadic nature of outbreaks, which complicate vaccine development. Recommendations include sustained investment, collaborative research, and flexible trial designs. Ultimately, a pan-filovirus vaccine would be a vital tool in global health preparedness and reaching that goal will require long-term vision and commitment from the international community.
